Aberdeen scanner study could improve brain tumour treatments
MRI scanners were invented at the University of Aberdeen 50 years ago, but the new FCI scanner is the only one of its type used on patients anywhere in the world.It can work at low and ultra-low magnetic fields which means it is capable of seeing how organs are affected by diseases in ways that were not previously possible.It can vary the strength of the magnetic field during the patient's scan - acting like multiple scanners and extracting more information about the tissues.The new technology can detect tumours without having to inject dye into the body, which can be associated with kidney damage and allergic reactions in some patients.The team of doctors and scientists involved will scan glioblastoma patients undergoing chemotherapy after surgery and chemoradiotherapy.
It is hoped the research will establish that, unlike conventional MRI scans, FCI can tell the difference between tumour growth and progression, and "pseudo-progression" which looks like a tumour but is not cancerous tissue.Prof Anne Kiltie, chair in clinical oncology at the University of Aberdeen, who is leading the study, said: "We already have evidence that FCI is effective in detecting tumours in breast tissue and brain damage in stroke patients."Applying this exciting new technology to glioblastoma patients could give us a much more accurate and detailed picture of what is going on in their brain."If we can detect true tumour progression early, we can swap the patient to a potentially more beneficial type of chemotherapy."Providing certainty will also reduce anxiety for both patients and relatives and improve the quality of life of patients."Prof Kiltie's role at the university is fully funded by the charity Friends of ANCHOR through its Dream Big appeal.Chief executive Sarah-Jane Hogg welcomed the "really promising" development and thanked donors and fundraisers for their support.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
21 minutes ago
- The Independent
Bluetongue has been detected in England. Here's what you should know
A tiny midge, no bigger than a pinhead, is bringing UK farming to its knees. The culprit? A strain of the bluetongue virus that's never been seen before. As of July 1, the whole of England has been classed as an 'infected area' due to bluetongue virus serotype 3 (BTV-3). There are movement restrictions and testing in place in Scotland, Wales and the island of Ireland. No animals from England – or that have passed through England – are allowed to attend this year's Royal Welsh Show on July 21-24, for example. The virus, which causes illness and death in sheep, cattle, goats and other ruminants, is spread by biting midges. Although it poses no risk to humans and can't be transmitted from one animal to another, the latest outbreak is more severe than previous ones. And it could cause lasting damage to UK farming. Bluetongue isn't new to the UK, however. A different strain, BTV-8 was detected in 2007 and contained. But BTV-3 is a different story. First detected in the Netherlands in late 2023, it was quickly spotted in the UK, where an early containment effort initially appeared successful. But the virus made a comeback in autumn 2024 – and this time it spread. On its second attempt, the virus was able to circulate and caused an outbreak. With little existing immunity, BTV-3 has now established itself, prompting concerns about animal welfare, food production and farming livelihoods. What does the disease do? Sheep tend to be the most severely affected, though all ruminants are at risk. Clinical signs are species-specific but can include swelling of the face, congestion, nasal discharge, ulcers in the mouth and nose, difficulty breathing and abortion or birth deformities. Bluetongue can cause the animal's tongue to swell. It can also turn blue from a lack of blood flow – although this is somewhat rare. Bluetongue disease causes suffering in animals, and while there is a vaccine, there is no treatment for the disease once it's contracted. BTV-3 appears to be more lethal than earlier strains. In the Netherlands, vets report that BTV-3 is causing more severe symptoms than BTV-8 did. Vets in England reported that in some herds 25-40% of cows failed to get pregnant, and there was a high rate of birth defects and stillborn calves. One farm in Suffolk started the calving season with 25% of their cows not pregnant and ended with just 48 calves from 97 cows. Belgium has seen a fall in calf births, reduced milk deliveries and higher mortality in small ruminants compared to the previous three years. How is it spread? Bluetongue virus is transmitted by midges from the Culicoides genus. These are tiny, biting insects that thrive in mild, wet conditions. Multiple midges can bite the same animal, and it only takes one of them to carry BTV before that animal becomes a host for further transmission. When animals are transported long distances, infected individuals can be bitten again and introduce the virus to previously uninfected midge populations. Climate change is making outbreaks like this more likely. Milder winters and cooler, wetter summers are ideal for midges, increasing both their numbers and their biting activity. While there's no danger to human health, the consequences of BTV-3 are far-reaching. Limitations on movement, exports and imports are being imposed to help prevent the spread of the disease, but this could also hamper farming practices and trade. The disease and its associated restrictions pose another source of stress for farmers, 95% of whom have ranked mental health as the biggest hidden problem in farming. Genetic pick and mix One of the reasons bluetongue is so tricky to manage is its ability to evolve. It has a segmented genome, meaning its genetic material, in this case RNA, is split into ten segments. This characteristic is exclusive to 'reassortment viruses' and means that they can easily exchange segments of RNA. It's like a genetic pick and mix with ten different types of sweets that come in an unlimited number of flavours. This allows BTV to create new, genetically distinct 'serotypes', which may have a selective advantage or a disadvantage. Those with an advantage will emerge and spread successfully, while those with a disadvantage will not emerge at all. This process, known as 'reassortment', is partly responsible for the numerous influenza pandemics throughout history and has even allowed diseases to jump the species barrier. Although bluetongue doesn't affect humans directly, its spread poses a growing threat to the UK's livestock sector and food supply. It's important to learn from other countries that are further along in the BTV-3 outbreak so that the likely effects can be anticipated in the UK.
The Independent
2 hours ago
- The Independent
Groundbreaking cancer trial to recruit patients within the NHS
A new immunotherapy drug trial for glioblastoma, the deadliest form of brain cancer, is now recruiting patients in the NHS. The trial follows a previous study where patient Ben Trotman's tumour vanished, and he has shown no signs of the disease for over two years, a rare outcome for glioblastoma. The NHS study will enrol 16 patients over 18 months, who will receive the immunotherapy drug ipilimumab before standard treatment. The trial was established in memory of Baroness Margaret McDonagh, who died from the disease, and was funded by over £1 million raised by her sister, Dame Siobhain McDonagh MP. Led by Consultant Medical Oncologist Dr Paul Mulholland, the trial aims to build on previous findings and offers significant hope for patients with this aggressive cancer. Dad's aggressive brain cancer vanishes after taking new drug
The Independent
3 hours ago
- The Independent
New tool could revolutionise skin cancer diagnosis
A groundbreaking artificial intelligence tool, developed by PhD student Tess Watt at Heriot-Watt University in Edinburgh, aims to revolutionise skin cancer diagnosis. The system allows patients to photograph skin complaints using a camera attached to an inexpensive Raspberry Pi device, which then analyses the image against a vast dataset for real-time diagnosis. Designed for early detection, the tool is intended to provide rapid assessments globally, particularly in remote regions, without requiring direct access to dermatologists or internet connectivity. The research team reports the tool is up to 85 per cent accurate, with ongoing efforts to enhance its diagnostic capabilities by accessing more skin lesion datasets. Discussions are underway with NHS Scotland for ethical approval, with a pilot project anticipated within the next one to two years, aiming for eventual widespread implementation.
